Replimune (REPL) Other Non-Current Liabilities (2018 - 2025)
Replimune's (REPL) quarterly Other Non-Current Liabilities came in at $693000.0 in Q4 2025, down 45.26% year-on-year from $1.3 million in Q4 2024, and down 26.35% quarter-over-quarter from $941000.0 in Q3 2025.
Replimune (REPL) Other Non-Current Liabilities (2018 - 2025) Analysis & Trends
Replimune has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $693000.0 for Q4 2025.
- Other Non-Current Liabilities for Q4 2025 came in at $693000.0, down 45.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $693000.0 (down 45.26% YoY), and the FY2025 annual result was $941000.0, up 19.72% from the prior year.
- Other Non-Current Liabilities came in at $693000.0 for Q4 2025 at Replimune, down from $941000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 million in Q4 2024 to a low of $472000.0 in Q1 2023.
- The 3-year median for Other Non-Current Liabilities is $786000.0 (2024), against an average of $787916.7.
- Across the five-year window, Other Non-Current Liabilities jumped 66.53% in 2024 and sank 45.26% in 2025, its largest moves.
- Replimune's Other Non-Current Liabilities stood at $793000.0 in 2023, then jumped by 59.65% to $1.3 million in 2024, then plunged by 45.26% to $693000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $693000.0 (Q4 2025), $941000.0 (Q3 2025), and $941000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 693,000.00 |
| Sep 30, 2025 | 941,000.00 |
| Jun 30, 2025 | 941,000.00 |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 786,000.00 |
| Jun 30, 2024 | 786,000.00 |
| Mar 31, 2024 | 786,000.00 |
| Dec 31, 2023 | 793,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Jun 30, 2023 | 578,000.00 |
| Mar 31, 2023 | 472,000.00 |
| Jun 30, 2018 | 7.09 Mn |
| Mar 31, 2018 | 1.64 Mn |